• By ICR Secretariat
  • Posted Tuesday, June 21, 2022

GSK claims first positive Phase 3 result for an RSV vaccine


  • GSK’s experimental vaccine for respiratory syncytial virus prevented disease in adults 60 and older, the company said Friday, clearing the way for the British drugmaker to ask regulators later this year to approve the shot.